Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Maiga, Mamoudou ^a   Agarwal, Nisheeth ^a,b   Ammerman, Nicole C ^a   Gupta, Radhika ^a   Guo, Haidan ^a   Maiga, Marama C ^a   Lun, Shichun ^a   Bishai, William R ^a,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Translational Health Science and Technology Institute   (India)

^c AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CILOSTAZOL; ISONIAZID; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TUMOR NECROSIS FACTOR ALPHA; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; TETRAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; FOOD AND DRUG ADMINISTRATION; LONG TERM CARE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES; ANIMAL; DISEASE MODEL; TIME; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); MURINAE;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; MICE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856526748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030749     Document Type: Article

References (32)

1. World Health Organization (2010) Global tuberculosis control 2010.
2. Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR, (2009) Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature 460 (7251): 98-102.
3. Russell DG, (2007) Who puts the tubercle in tuberculosis? Nat Rev Microbiol 5 (1): 39-47.
4. Agarwal N, Bishai WR, (2009) cAMP signaling in Mycobacterium tuberculosis. Indian J Exp Biol 47 (6): 393-400.
5. Johannessen M, Moens U, (2007) Multisite phosphorylation of the cAMP response element-binding protein (CREB) by a diversity of protein kinases. Front Biosci 12: 1814-1832.
6. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M, (2008) Cyclic AMP: Master regulator of innate immune cell function. Am J Respir Cell Mol Biol 39 (2): 127-132.
7. Omori K, Kotera J, (2007) Overview of PDEs and their regulation. Circ Res 100 (3): 309-327.
8. Bender AT, Beavo JA, (2006) Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 58 (3): 488-520.
9. Szczypka M, Obminska-Mrukowicz B, (2010) Modulating effects of nonselective and selective phosphodiesterase inhibitors on lymphocyte subsets and humoral immune response in mice. Pharmacol Rep 62 (6): 1148-1158.
10. Lowrie DB, Jackett PS, Ratcliffe NA, (1975) Mycobacterium microti may protect itself from intracellular destruction by releasing cyclic AMP into phagosomes. Nature 254 (5501): 600-602.
11. Shenoy AR, Visweswariah SS, (2006) New messages from old messengers: CAMP and mycobacteria. Trends Microbiol 14 (12): 543-550.
12. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, et al. (2005) Ipr1 gene mediates innate immunity to tuberculosis. Nature 434 (7034): 767-772.
13. Jassal MS, Bishai WR, (2010) Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis 50 (Suppl 3): S156-64.
14. Lienhardt C, Vernon A, Raviglione MC, (2010) New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 16 (3): 186-193.
15. Nuermberger EL, Spigelman MK, Yew WW, (2010) Current development and future prospects in chemotherapy of tuberculosis. Respirology 15 (5): 764-778.
16. World Health Organization (2007) Report of the expert consultation on immunotherapeutic interventions for tuberculosis.
17. Wallis RS, (2005) Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 41 (2): 201-208.
18. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, et al. (2009) Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 30 (4): 769-82, ix.
19. Mayanja-Kizza H, Jones-Lopez E, Okwera A, Wallis RS, Ellner JJ, et al. (2005) Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: A phase 2 clinical trial in Uganda. J Infect Dis 191 (6): 856-865.
20. Harris J, Keane J, (2010) How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 161 (1): 1-9.
21. Quesniaux VF, Jacobs M, Allie N, Grivennikov S, Nedospasov SA, et al. (2010) TNF in host resistance to tuberculosis infection. Curr Dir Autoimmun 11: 157-179.
22. Paige C, Bishai WR, (2010) Penitentiary or penthouse condo: The tuberculous granuloma from the microbe's point of view. Cell Microbiol 12 (3): 301-309.
23. Hattori Y, Suzuki K, Tomizawa A, Hirama N, Okayasu T, et al. (2009) Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc Res 81 (1): 133-139.
24. Gao L, Wang F, Wang B, Gong B, Zhang J, et al. (2006) Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression. J Pharmacol Exp Ther 318 (1): 53-58.
25. Aizawa T, Wei H, Miano JM, Abe J, Berk BC, et al. (2003) Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 93 (5): 406-413.
26. Mendes JB, Campos PP, Rocha MA, Andrade SP, (2009) Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. Life Sci 84 (15-16): 537-543.
27. Courtade ET, Tsuda T, Thomas CR, Dannenberg AM, (1975) Capillary density in developing and healing tuberculous lesions produced by BCG in rabbits. A quantitative study. Am J Pathol 78 (2): 243-260.
28. Koo MS, Manca C, Yang G, O'Brien P, Sung N, et al. (2011) Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One 6 (2): e17091.
29. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, et al. (2011) Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 7 (9): e1002262.
30. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, et al. (2011) Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 179 (1): 289-301.
31. Spina D, (2008) PDE4 inhibitors: Current status. Br J Pharmacol 155 (3): 308-315.
32. Dhillon J, Dickinson JM, Sole K, Mitchison DA, (1996) Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 40 (3): 552-555.